<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00862082</url>
  </required_header>
  <id_info>
    <org_study_id>PR104-2002</org_study_id>
    <nct_id>NCT00862082</nct_id>
    <nct_alias>NCT00838604</nct_alias>
  </id_info>
  <brief_title>Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>A Randomized Phase I/II, Multi-Center, Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Proacta, Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Proacta, Incorporated</source>
  <brief_summary>
    <textblock>
      The current understanding of PR104 justifies the evaluation of PR104 with sorafenib in
      patients with hepatocellular carcinoma. These include:

        -  Hypoxia. Hepatocellular Carcinoma (HCC) is likely to demonstrate a level of hypoxia
           sufficient to activate PR104 to its active metabolites PR104H and PR104M. In addition,
           in preclinical models, sorafenib has been demonstrated to increase the degree of hypoxia
           in tumors following treatment.

        -  Non-overlapping toxicity. PR104 and sorafenib do not share major toxicities. It is
           anticipated that both drugs can be administered at their full single agent dose when
           used in combination.

        -  Aldo-keto reductase 1C3 (AKR1C3). HCC has been shown to express high levels of AKR1C3
           which should lead to selective activation of PR104 within both hypoxic and oxic HCC
           cells.

        -  Preclinical data. The use of sorafenib and PR104 alone and in combination in a
           hepatocellular carcinoma model demonstrates activity of PR104 as a single agent and
           increased activity when PR104 and sorafenib are used in combination.

      The current study will provide an estimate of the activity of PR104 in subjects with HCC.
      This information will prove valuable in defining the future clinical development of PR104,
      and in determining if PR104 has sufficient activity in HCC to warrant a larger phase III
      registration study in this indication.

      Primary objectives

        -  Phase I: Determine the maximum tolerated dose (MTD) of PR104 when used in combination
           with standard dose sorafenib

        -  Phase II: Estimate the response rate (RR) of PR104/sorafenib [Note: Phase II was never
           initiated]

      Secondary objectives

        -  Evaluate survival

        -  Evaluate Progression Free Survival (PFS)

        -  Evaluate time to progression (TTP)

        -  Evaluate safety

        -  Evaluate the pharmacokinetics (PK) of sorafenib, PR104 and PR104 metabolites

        -  Collect diagnostic biopsy samples for the determination of aldo-keto reductase 1C3

        -  Collect plasma samples for assessment of potential biomarkers of tumor hypoxia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized phase I/II, multi-center, open-label, study with a single arm phase I portion to
      determine the appropriate dose of PR104 combined with sorafenib, followed by a phase II
      portion with randomization between sorafenib and sorafenib/PR104.

      Following informed consent, subjects will undergo baseline evaluation with history, physical
      exams, blood work and disease assessment. Selected subjects will undergo PK assessment of
      sorafenib, PR104 and PR104 metabolites.

      In the phase I portion of the study, the starting dose of PR104 will be 770 mg/mg2 in
      combination with standard dose sorafenib. PR104 will be administered on an every 4 week
      schedule with the dose of PR104 escalated in a standard phase I fashion (3 subjects per
      cohort, dose escalation between cohorts) in order to determine the MTD of PR104. Cohorts may
      be expanded up to 12 subjects to better define toxicity at a particular dose level. Following
      determination of the MTD of PR104, new subjects will be entered into the phase II portion of
      the study. [Note: the Phase II portion was never initiated]

      In the phase II portion of the study, subjects will be randomized between sorafenib, 400 mg,
      by mouth (PO), twice a day (the approved dose and schedule) versus sorafenib with PR104 at
      the dose determined in the phase I portion of the study. PR104 will be administered every 4
      weeks (one cycle). Subjects will be evaluated each week during cycle 1 and every two weeks
      thereafter. A disease assessment will be performed after every two cycles. Subjects with
      progression will be removed from study. Subjects with a response or stable disease may
      continue on study if this is considered beneficial by their physician.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PR104 plus sorafenib was poorly tolerated in patients with advanced HCC
  </why_stopped>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of PR104 When Used in Combination With Standard Dose Sorafenib in the Phase I Population</measure>
    <time_frame>4 weeks (1 cycle)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability: Serious Adverse Events</measure>
    <time_frame>30 days following the last administration of study treatment</time_frame>
    <description>The number of participants with at least one Serious Adverse Event was measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics [Maximum Plasma Concentration (Cmax)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group)</measure>
    <time_frame>Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics [Half Life (T1/2)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group)</measure>
    <time_frame>Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics [Area Under the Curve(AUC)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group)</measure>
    <time_frame>Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmax) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group)</measure>
    <time_frame>Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (T1/2) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group)</measure>
    <time_frame>Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUC) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group)</measure>
    <time_frame>Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>PR104 + Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PR104 will be administered IV once every four weeks, in addition to 400mg sorafenib PO twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PR104 550 mg/m^2 + sorafenib</intervention_name>
    <description>550 mg/m^2 PR104 IV on day 1 of each 28 day cycle + 400 mg sorafenib PO twice daily. Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>PR104 + Sorafenib</arm_group_label>
    <other_name>PR-104</other_name>
    <other_name>Nexavar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PR104 770 mg/m^2 + sorafenib</intervention_name>
    <description>770 mg/m^2 PR104 IV on day 1 of each 28 day cycle + 400 mg sorafenib PO twice daily. Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>PR104 + Sorafenib</arm_group_label>
    <other_name>PR-104</other_name>
    <other_name>Nexavar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced-stage hepatocellular carcinoma considered non-operable that is suitable for
             treatment with sorafenib. Subjects who have demonstrated progression following initial
             surgical or locoregional therapy are eligible

          -  Confirmed hepatocellular carcinoma by pathological analysis (tissue aspirate or
             biopsy)

          -  No previous systemic therapy for hepatocellular carcinoma

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          -  Child-Pugh liver function class A

          -  Life expectancy of 12 weeks or more

          -  Adequate hematologic function [Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L;
             platelet count ≥100×10^9 per liter; hemoglobin ≥8.5 g per deciliter maintained in the
             absence of red blood cell transfusions; and prothrombin time international normalized
             ratio ≤1.7; or prothrombin time ≤2 seconds above control]

          -  Adequate hepatic function (albumin ≥2.8 g per deciliter; total bilirubin ≤2 mg per
             deciliter [51.3 μmol per liter]; and alanine aminotransferase and aspartate
             aminotransferase ≤5 times the upper limit of the normal range)

          -  Adequate renal function (serum creatinine ≤1.5 times the upper limit of the normal
             range or creatinine clearance ≥60 mL/min).

          -  At least one untreated target lesion that could be measured in one dimension,
             according to the Response Evaluation Criteria in Solid Tumors (RECIST)

          -  Concomitant systemic antiviral therapy allowed

        Exclusion Criteria:

          -  Previous molecularly targeted therapies or any other systemic treatment for
             hepatocellular carcinoma

          -  Active concomitant malignancy likely to effect any of the primary or secondary outcome
             measures in the current study

          -  Women who are pregnant, breast-feeding or planning to become pregnant during the study

          -  Men or women of reproductive-potential who are unwilling to use an effective method of
             contraception during the study and for 30 days following the last dose of study
             medication

          -  Evidence of a significant medical disorder or laboratory finding that, in the opinion
             of the Investigator, compromises the subject's safety during study participation such
             as: uncontrolled infection or infection requiring a concomitant parenteral antibiotic;
             uncontrolled diabetes; congestive heart failure; myocardial infarction within 6 months
             of study; chronic renal disease; or coagulopathy (excluding prophylactic
             anticoagulation)

          -  Active central nervous system metastatic disease requiring intervention

          -  Less than four weeks since major surgery

          -  Known Human Immunodeficiency Virus (HIV) positivity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Clinical Oncology Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Oncology/Hematology</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <state>New Territories</state>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi Mei Medical Center, Liouying</name>
      <address>
        <city>T'ai-nan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cathay General Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>10630</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2009</study_first_submitted>
  <study_first_submitted_qc>March 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2009</study_first_posted>
  <results_first_submitted>May 31, 2011</results_first_submitted>
  <results_first_submitted_qc>July 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 23, 2013</results_first_posted>
  <last_update_submitted>July 19, 2013</last_update_submitted>
  <last_update_submitted_qc>July 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PR104 550 mg/m^2 + Sorafenib</title>
          <description>550 mg/m^2 PR104 administered IV every 4 weeks + Standard dose sorafenib (400 mg PO twice daily)</description>
        </group>
        <group group_id="P2">
          <title>PR104 770 mg/m^2 + Sorafenib</title>
          <description>770 mg/m^2 PR104 administered IV every 4 weeks + Standard dose sorafenib (400 mg PO twice daily)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Sponsor decision to terminate the study</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PR104 550 mg/m^2 + Sorafenib</title>
          <description>550 mg/m^2 PR104 administered IV every 4 weeks + Standard dose sorafenib (400 mg PO twice daily)</description>
        </group>
        <group group_id="B2">
          <title>PR104 770 mg/m^2 + Sorafenib</title>
          <description>770 mg/m^2 PR104 administered IV every 4 weeks + Standard dose sorafenib (400 mg PO twice daily)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="13"/>
                    <measurement group_id="B2" value="59" spread="13"/>
                    <measurement group_id="B3" value="58" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) of PR104 When Used in Combination With Standard Dose Sorafenib in the Phase I Population</title>
        <time_frame>4 weeks (1 cycle)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohorts 1 and 2</title>
            <description>770 and 550 mg/m^2 PR104 administered IV every 4 weeks + Standard dose sorafenib (400 mg PO twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD) of PR104 When Used in Combination With Standard Dose Sorafenib in the Phase I Population</title>
          <units>mg/m2</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There were no DLTs, however myelosuppression in several patients led to the decision to discontinue the study; therefore, a MTD was not determined.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability: Serious Adverse Events</title>
        <description>The number of participants with at least one Serious Adverse Event was measured.</description>
        <time_frame>30 days following the last administration of study treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>770 mg/m^2 PR104 administered IV every 4 weeks + Standard dose sorafenib (400 mg PO twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>550 mg/m^2 PR104 administered IV every 4 weeks + Standard dose sorafenib (400 mg PO twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability: Serious Adverse Events</title>
          <description>The number of participants with at least one Serious Adverse Event was measured.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics [Maximum Plasma Concentration (Cmax)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group)</title>
        <time_frame>Day 1 of Cycles 1 and 2</time_frame>
        <population>Participation in pharmacokinetic (PK) sampling was optional to subjects, therefore not all subjects in the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PR104</title>
          </group>
          <group group_id="O2">
            <title>PR104A</title>
            <description>major plasma metabolite</description>
          </group>
          <group group_id="O3">
            <title>PR104G</title>
            <description>major plasma metabolite</description>
          </group>
          <group group_id="O4">
            <title>PR104S1</title>
            <description>semi-mustard metabolite</description>
          </group>
          <group group_id="O5">
            <title>PR104H</title>
            <description>activated reduced metabolites</description>
          </group>
          <group group_id="O6">
            <title>PR104M</title>
            <description>activated reduced metabolites</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics [Maximum Plasma Concentration (Cmax)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group)</title>
          <population>Participation in pharmacokinetic (PK) sampling was optional to subjects, therefore not all subjects in the study were analyzed.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax Cycle 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="3.2"/>
                    <measurement group_id="O2" value="7.6" spread="1.9"/>
                    <measurement group_id="O3" value="9.6" spread="2.3"/>
                    <measurement group_id="O4" value="0.17" spread="0.15"/>
                    <measurement group_id="O5" value="0.21" spread="0.11"/>
                    <measurement group_id="O6" value="0.04" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax Cycle 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="3.3"/>
                    <measurement group_id="O2" value="7.6" spread="1.0"/>
                    <measurement group_id="O3" value="10.4" spread="2.2"/>
                    <measurement group_id="O4" value="0.18" spread="0.07"/>
                    <measurement group_id="O5" value="0.20" spread="0.05"/>
                    <measurement group_id="O6" value="0.04" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics [Half Life (T1/2)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group)</title>
        <time_frame>Day 1 of Cycles 1 and 2</time_frame>
        <population>Participation in PK sampling was optional to subjects, therefore not all subjects in the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PR104</title>
          </group>
          <group group_id="O2">
            <title>PR104A</title>
            <description>major plasma metabolite</description>
          </group>
          <group group_id="O3">
            <title>PR104G</title>
            <description>major plasma metabolite</description>
          </group>
          <group group_id="O4">
            <title>PR104S1</title>
            <description>semi-mustard metabolite</description>
          </group>
          <group group_id="O5">
            <title>PR104H</title>
            <description>activated reduced metabolites</description>
          </group>
          <group group_id="O6">
            <title>PR104M</title>
            <description>activated reduced metabolites</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics [Half Life (T1/2)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group)</title>
          <population>Participation in PK sampling was optional to subjects, therefore not all subjects in the study were analyzed.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T1/2 Cycle 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.10"/>
                    <measurement group_id="O2" value="0.75" spread="0.35"/>
                    <measurement group_id="O3" value="0.62" spread="0.08"/>
                    <measurement group_id="O4" value="0.87" spread="0.11"/>
                    <measurement group_id="O5" value="1.37" spread="0.18"/>
                    <measurement group_id="O6" value="3.57" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1/2 Cycle 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.11"/>
                    <measurement group_id="O2" value="0.85" spread="0.20"/>
                    <measurement group_id="O3" value="0.67" spread="0.17"/>
                    <measurement group_id="O4" value="0.79" spread="0.14"/>
                    <measurement group_id="O5" value="1.05" spread="0.35"/>
                    <measurement group_id="O6" value="02.93" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics [Area Under the Curve(AUC)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group)</title>
        <time_frame>Day 1 of Cycles 1 and 2</time_frame>
        <population>Participation in PK sampling was optional to subjects, therefore not all subjects in the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PR104</title>
          </group>
          <group group_id="O2">
            <title>PR104A</title>
            <description>major plasma metabolite</description>
          </group>
          <group group_id="O3">
            <title>PR104G</title>
            <description>major plasma metabolite</description>
          </group>
          <group group_id="O4">
            <title>PR104S1</title>
            <description>semi-mustard metabolite</description>
          </group>
          <group group_id="O5">
            <title>PR104H</title>
            <description>activated reduced metabolites</description>
          </group>
          <group group_id="O6">
            <title>PR104M</title>
            <description>activated reduced metabolites</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics [Area Under the Curve(AUC)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group)</title>
          <population>Participation in PK sampling was optional to subjects, therefore not all subjects in the study were analyzed.</population>
          <units>ng.h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC Cycle 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="3.2"/>
                    <measurement group_id="O2" value="11.0" spread="4.4"/>
                    <measurement group_id="O3" value="12.3" spread="1.3"/>
                    <measurement group_id="O4" value="0.26" spread="0.23"/>
                    <measurement group_id="O5" value="0.47" spread="0.27"/>
                    <measurement group_id="O6" value="0.22" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC Cycle 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="2.9"/>
                    <measurement group_id="O2" value="10.6" spread="0.1"/>
                    <measurement group_id="O3" value="15.8" spread="2.9"/>
                    <measurement group_id="O4" value="0.28" spread="0.10"/>
                    <measurement group_id="O5" value="0.42" spread="0.04"/>
                    <measurement group_id="O6" value="0.19" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (Cmax) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group)</title>
        <time_frame>Day 1 of Cycles 1 and 2</time_frame>
        <population>Participation in PK sampling was optional to subjects, therefore not all subjects in the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PR104</title>
          </group>
          <group group_id="O2">
            <title>PR104A</title>
            <description>major plasma metabolite</description>
          </group>
          <group group_id="O3">
            <title>PR104G</title>
            <description>major plasma metabolite</description>
          </group>
          <group group_id="O4">
            <title>PR104S1</title>
            <description>semi-mustard metabolite</description>
          </group>
          <group group_id="O5">
            <title>PR104H</title>
            <description>activated reduced metabolites</description>
          </group>
          <group group_id="O6">
            <title>PR104M</title>
            <description>activated reduced metabolites</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (Cmax) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group)</title>
          <population>Participation in PK sampling was optional to subjects, therefore not all subjects in the study were analyzed.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax Cycle 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="1.1"/>
                    <measurement group_id="O2" value="15.8" spread="8.9"/>
                    <measurement group_id="O3" value="4.9">Not determined for PR-104G due to the availability of only one subject's dataset from each cycle</measurement>
                    <measurement group_id="O4" value="0.21" spread="0.18"/>
                    <measurement group_id="O5" value="0.72" spread="0.80"/>
                    <measurement group_id="O6" value="0.12" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax Cycle 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="0.7"/>
                    <measurement group_id="O2" value="14.6" spread="10.4"/>
                    <measurement group_id="O3" value="5.8">Not determined for PR-104G due to the availability of only one subject's dataset from each cycle.</measurement>
                    <measurement group_id="O4" value="0.17" spread="0.17"/>
                    <measurement group_id="O5" value="0.69" spread="0.78"/>
                    <measurement group_id="O6" value="0.16" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (T1/2) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group)</title>
        <time_frame>Day 1 of Cycles 1 and 2</time_frame>
        <population>Participation in PK sampling was optional to subjects, therefore not all subjects in the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PR104</title>
          </group>
          <group group_id="O2">
            <title>PR104A</title>
            <description>major plasma metabolite</description>
          </group>
          <group group_id="O3">
            <title>PR104G</title>
            <description>major plasma metabolite</description>
          </group>
          <group group_id="O4">
            <title>PR104S1</title>
            <description>semi-mustard metabolite</description>
          </group>
          <group group_id="O5">
            <title>PR104H</title>
            <description>activated reduced metabolites</description>
          </group>
          <group group_id="O6">
            <title>PR104M</title>
            <description>activated reduced metabolites</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (T1/2) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group)</title>
          <population>Participation in PK sampling was optional to subjects, therefore not all subjects in the study were analyzed.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T1/2 Cycle 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.01"/>
                    <measurement group_id="O2" value="0.68" spread="0.04"/>
                    <measurement group_id="O3" value="0.53">Not determined for PR-104G due to the availability of only one subject's dataset from each cycle.</measurement>
                    <measurement group_id="O4" value="0.69" spread="0.20"/>
                    <measurement group_id="O5" value="0.84" spread="0.34"/>
                    <measurement group_id="O6" value="1.02" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1/2 Cycle 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.01"/>
                    <measurement group_id="O2" value="0.79" spread="0.23"/>
                    <measurement group_id="O3" value="0.50">Not determined for PR-104G due to the availability of only one subject's dataset from each cycle.</measurement>
                    <measurement group_id="O4" value="0.90" spread="0.44"/>
                    <measurement group_id="O5" value="0.91" spread="0.25"/>
                    <measurement group_id="O6" value="0.99" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (AUC) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group)</title>
        <time_frame>Day 1 of Cycles 1 and 2</time_frame>
        <population>Participation in PK sampling was optional to subjects, therefore not all subjects in the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PR104</title>
          </group>
          <group group_id="O2">
            <title>PR104A</title>
            <description>major plasma metabolite</description>
          </group>
          <group group_id="O3">
            <title>PR104G</title>
            <description>major plasma metabolite</description>
          </group>
          <group group_id="O4">
            <title>PR104S1</title>
            <description>semi-mustard metabolite</description>
          </group>
          <group group_id="O5">
            <title>PR104H</title>
            <description>activated reduced metabolites</description>
          </group>
          <group group_id="O6">
            <title>PR104M</title>
            <description>activated reduced metabolites</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (AUC) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group)</title>
          <population>Participation in PK sampling was optional to subjects, therefore not all subjects in the study were analyzed.</population>
          <units>ng.h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC Cycle 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.8"/>
                    <measurement group_id="O2" value="19.7" spread="9.7"/>
                    <measurement group_id="O3" value="6.4">Not determined for PR-104G due to the availability of only one subject's dataset from each cycle.</measurement>
                    <measurement group_id="O4" value="0.30" spread="0.23"/>
                    <measurement group_id="O5" value="0.81" spread="0.71"/>
                    <measurement group_id="O6" value="0.18" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC Cycle 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.6"/>
                    <measurement group_id="O2" value="22.7" spread="18.2"/>
                    <measurement group_id="O3" value="7.6">Not determined for PR-104G due to the availability of only one subject's dataset from each cycle.</measurement>
                    <measurement group_id="O4" value="0.31" spread="0.21"/>
                    <measurement group_id="O5" value="1.07" spread="1.02"/>
                    <measurement group_id="O6" value="0.25" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PR104 550 mg/m^2 + Sorafenib</title>
          <description>550 mg/m^2 PR104 administered IV every 4 weeks + Standard dose sorafenib (400 mg PO twice daily)</description>
        </group>
        <group group_id="E2">
          <title>PR104 770 mg/m^2 + Sorafenib</title>
          <description>770 mg/m^2 PR104 administered IV every 4 weeks + Standard dose sorafenib (400 mg PO twice daily)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Decrease in general condition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fever in absence of neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Coordination abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Leukocytoclastic vasulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Single site data may be published/presented prior to the publication of multi-center data from overall study if agreed to by the sponsor in writing, or 12 months have elapsed following termination or completion of the study, whichever comes first.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed. Phase II part of study never initiated.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Director of Clinical Development</name_or_title>
      <organization>Proacta, Inc.</organization>
      <phone>858-642-0386</phone>
      <email>clinicalops@proacta.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

